| [1] |
Schultze JL. Teaching ′big data′ analysis to young immunologists[J]. Nat Immunol, 2015, 16(9): 902-905.
|
| [2] |
Friedman AA,Letai A,Fisher DE, et al. Precision medicine for cancer with next-generation functional diagnostics[J]. Nat Rev Cancer, 2015, 15(12): 747-756.
|
| [3] |
Reinert T,Schøler LV,Thomsen R, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery[J]. Gut, 2016, 65(4): 625-634.
|
| [4] |
Bokemeyer, C., Bondarenko, I.,Hartmann, J., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study[J]. Ann Oncol, 2011, 22(7): 1535-1546.
|
| [5] |
Douillard, J., Oliner, K.,Siena, S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer[J]. N Engl J Med, 2013, 369(11): 1023-1034.
|
| [6] |
Sartore-Bianchi, A., Martini, M.,Molinari, F., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies[J]. Cancer Res, 2009, 69(5): 1851-1857.
|
| [7] |
De Roock, W., Claes, B.,Bernasconi, D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis[J]. Lancet Oncol, 2010, 11(8): 753-762.
|
| [8] |
Tabernero J,Lenz HJ,Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial[J]. Lancet Oncol, 2015, 6(8): 937-948.
|
| [9] |
Esteban-Jurado C,Vila-Casadesús M,Garre P, et al. Whole-exome sequencing identifies rare pathogenic variants in new predisposition genes for familial colorectal cancer[J]. Genet Med, 2015, 17(2): 131-142.
|
| [10] |
Chubb D,Broderick P,Frampton M, et al. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing[J]. J Clin Oncol, 2015, 33(5): 426-432.
|
| [11] |
Leichman L,Groshen S,O’Neil BH, et al. Phase II study of Olaparib (AZD-2281) after standard systemic therapies for disseminated colorectal cancer[J]. Oncologist, 2016, 21(2): 172-177.
|
| [12] |
Garrido-Laguna I,Hong DS,Janku F, et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors[J]. PLoS One, 2012, 7(5): e38033.
|
| [13] |
Tolcher AW,Khan K,Ong M, et al. Antitumor activity in RAS-driven tumors by blocking AKT and MEK[J]. Clin Cancer Res, 2015, 21(4): 739-748.
|
| [14] |
Do K,O′Sullivan Coyne G,Chen AP. An overview of the NCI precision medicine trials-NCI MATCH and MPACT[J]. Chin Clin Oncol, 2015, 4(3): 31.
|
| [15] |
Jovelet C,Ileana E,Le Deley MC, et al. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial[J]. Clin Cancer Res, 2016, 22(12): 2960-2968.
|
| [16] |
Rodon J,Soria JC,Berger R, et al. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial[J]. Ann Oncol, 2015, 26(8): 1791-1798.
|
| [17] |
Zhang B,Wang J,Wang X, et al. Proteogenomic characterization of human colon and rectal cancer[J]. Nature, 2014, 513(7518): 382-387.
|
| [18] |
Bertotti A,Papp E,Jones S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer[J]. Nature, 2015, 526(7572): 263-267.
|
| [19] |
Roychowdhury S,Chinnaiyan AM. Translating cancer genomes and transcriptomes for precision oncology[J]. CA Cancer J Clin, 2016, 66(1): 75-88.
|
| [20] |
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer[J]. Nature, 2012, 487(7407): 330-337.
|